Zymeworks acquires Theravance Biopharma for $929 million

Statements (6)

1. ▲ Bullish

   Truist Securities initiated coverage of Zymeworks Inc. with a Buy rating and a $28 price target

   finance.yahoo.comJun 30, 2026 13:21 UTC
2. ● Neutral

   Zymeworks agrees to acquire Theravance Biopharma for $929 million in a cash transaction

   finance.yahoo.comJun 30, 2026 08:26 UTCHigh importance
3. ▲ Bullish

   Theravance Biopharma's stock price is likely to rise following the acquisition agreement with Zymeworks.

   finance.yahoo.comJun 30, 2026 08:26 UTC
4. ▼ Bearish

   Theravance Biopharma Inc. shares are likely to face pressure as Zymeworks Inc. acquires it for US$929-million in cash.

   theglobeandmail.comJun 29, 2026 21:34 UTC
5. ● Neutral

   Zymeworks Inc. is acquiring Theravance Biopharma Inc. for US$929 million in cash

   theglobeandmail.comJun 29, 2026 21:34 UTCHigh importance
6. ▲ Bullish

   Zymeworks is near a $929 million deal for Theravance

   bloomberg.comJun 29, 2026 09:00 UTCHigh importance